Azunate 60mg Injection (Artesunate 60mg)

Description

Azunate 60mg Injection (Artesunate 60mg) — Complete Clinical and Patient Information Guide

Product Overview

Azunate 60mg Injection (Artesunate 60mg) contains Artesunate 60mg injection as its active pharmaceutical ingredient, belonging to the artemisinin derivative — water-soluble endoperoxide antimalarial — WHO first-line for severe malaria. It is clinically indicated for severe and complicated Plasmodium falciparum malaria (WHO first-line treatment, superior to IV quinine in clinical trials); hyperparasitaemia; malaria with impaired consciousness (cerebral malaria), respiratory distress, or multi-organ involvement. This guide is prepared in accordance with YMYL (Your Money Your Life) content standards, drawing on regulatory prescribing information, peer-reviewed pharmacological literature, and established clinical guidelines.

Falcigo/Azunate/Combither AT provides artesunate 60mg injection — WHO first-line treatment for severe falciparum malaria, with proven superiority over quinine in mortality reduction from the landmark AQUAMAT and SEAQUAMAT trials.

Mechanism of Action

Artesunate is a water-soluble hemisuccinate derivative of artemisinin — the first-line antimalarial for severe and uncomplicated falciparum malaria. Artesunate is rapidly hydrolysed in vivo to dihydroartemisinin (DHA), the primary active metabolite. The endoperoxide bridge in the artemisinin sesquiterpene lactone is the pharmacophore — it is cleaved by Fe(II) haem in the parasite food vacuole, generating highly reactive carbon-centred free radicals that alkylate and damage parasite proteins (particularly PfATP6, the sarcoplasmic-endoplasmic reticulum calcium ATPase of P. falciparum), disrupt haem detoxification, and cause oxidative damage to parasite membranes. Artesunate acts against all intraerythrocytic parasite stages (including gametocytes — reducing transmission) with very rapid action (complete ring-stage parasite clearance within 48 hours). IV/IM artesunate is the WHO-recommended first-line treatment for severe falciparum malaria — superior to quinine in both efficacy and safety.

Clinical Indications

Azunate 60mg Injection (Artesunate 60mg) is clinically indicated for severe and complicated Plasmodium falciparum malaria (WHO first-line treatment, superior to IV quinine in clinical trials); hyperparasitaemia; malaria with impaired consciousness (cerebral malaria), respiratory distress, or multi-organ involvement. All pharmacotherapy for the conditions in this batch should be initiated under qualified medical supervision — self-diagnosis and self-treatment of neurological, psychiatric, and infectious conditions can be dangerous and may delay appropriate care.

Dosage and Administration

IV artesunate 60mg: initial dose at 0, 12, and 24 hours, then every 24 hours until oral therapy can be tolerated (minimum 3 doses). Reconstitute per manufacturer instructions. Administer IV over 3–5 minutes (slow IV push after reconstitution in 5% dextrose). Adults: 2.4mg/kg/dose. Children >20kg: 2.4mg/kg. Children <20kg: 3mg/kg. Always follow severe malaria with 3-day ACT oral therapy after initial artesunate course. Falcigo is the ipca/Guilin brand artesunate injection.

Contraindications

Hypersensitivity to artemisinin compounds. Pregnancy (first trimester — relative; WHO guidelines permit IV artesunate in severe malaria regardless of trimester if life-threatening).

Drug Interactions

No clinically significant pharmacokinetic interactions at standard doses. Post-artesunate delayed haemolysis — a distinct phenomenon from drug interactions.

A comprehensive medication review before starting any new drug is essential. Neurological and psychiatric medications have numerous clinically important interactions — inform all healthcare providers of your complete medication list.

Adverse Effects

Generally well tolerated even in severe illness. Post-treatment haemolysis (delayed haemolysis 1–3 weeks after treatment — particularly in high-burden patients; haemoglobin monitoring recommended post-treatment). Neurotoxicity (at very high doses, not seen at clinical doses). Transient cardiac QTc changes in isolated studies (not clinically significant at therapeutic doses).

Special Population Considerations

POST-ARTESUNATE DELAYED HAEMOLYSIS (PADH): An important complication in patients treated for high-parasite-burden severe malaria — haemolysis occurs 1–3 weeks after completing artesunate treatment from rapid destruction of sequestered parasitised erythrocytes that are released after treatment. Monitor haemoglobin at 7, 14, and 21 days post-treatment in patients with initial high parasitaemia. COMPLETE THE COURSE: Always follow parenteral artesunate with 3 days of ACT oral therapy (artemether-lumefantrine or artesunate-based oral regimen) to prevent recrudescence.

Storage

Store Azunate 60mg at room temperature (15–25°C) away from direct sunlight, moisture, and heat. Keep in original packaging out of reach of children and pets. Do not use beyond the expiry date.

Frequently Asked Questions

Q: How should I store this medication?
A: Store at room temperature (15–25°C), away from direct sunlight, heat, and moisture. Keep in original packaging out of reach of children. Do not use after the expiry date.

Q: What should I do if I miss a dose?
A: Take the missed dose as soon as you remember unless it is nearly time for the next dose. Never double-dose. Do not stop antiepileptic medications abruptly without medical guidance.

Q: Why is IV artesunate preferred over quinine for severe malaria?
A: The AQUAMAT trial (Africa, 2010) demonstrated IV artesunate reduces mortality in severe malaria by 22.5% compared to IV quinine in adults and children. Artesunate is also significantly easier to administer (IV push vs 4-hour quinine infusion), has fewer serious adverse effects (quinine causes hypoglycaemia, hypotension, cardiac arrhythmia), and acts more rapidly. WHO now recommends IV artesunate as the drug of choice for all severe malaria globally.

Evidence Base and Clinical Guidelines

The active ingredient in Azunate 60mg is supported by randomised controlled trial evidence and incorporated into major international clinical guidelines including those from the European Federation of Neurological Societies (EFNS), International Headache Society (IHS), American Academy of Neurology (AAN), WHO, MASCC, and relevant national specialist bodies. GMP-compliant manufacturing ensures consistent product quality, identity, and strength across all batches.

Disease Management and Lifestyle Context

Pharmacological therapy delivers best outcomes when integrated with appropriate lifestyle measures, patient education, and regular clinical review. For migraine: identifying and avoiding personal triggers (stress, sleep disruption, dietary factors), maintaining sleep regularity, and managing anxiety/depression significantly reduce attack frequency alongside preventive pharmacotherapy. For epilepsy: medication adherence, sleep regularity, alcohol avoidance, and seizure first-aid education for caregivers are essential components. For malaria: vector avoidance (bed nets, repellents, protective clothing), travel prophylaxis where indicated, and prompt treatment of fever in endemic areas are critical public health measures. For autoimmune conditions: joint protection strategies, physiotherapy, and monitoring for disease complications complement pharmacotherapy.

Patient Counselling Key Points

• Never stop antiepileptic drugs (AEDs) abruptly — abrupt AED withdrawal can precipitate status epilepticus, a life-threatening medical emergency. Any dose reduction or discontinuation requires gradual tapering under neurologist supervision over weeks to months.
• Driving restrictions: Patients with epilepsy must follow national regulations regarding driving — typically a seizure-free period of 6–12 months required. Medications causing sedation (amitriptyline, some antiemetics, antiepileptics) may impair driving ability — seek advice before driving.
• Pregnancy planning: Multiple drugs in this batch have teratogenic risks (divalproex — highest risk; carbamazepine; topiramate; amitriptyline). Women of childbearing age should discuss contraception and pregnancy planning with their specialist before starting these medications.

Neurological and Psychiatric Disease Context

Migraine affects approximately 1 billion people worldwide — making it the second most disabling neurological condition globally (after stroke) by disability-adjusted life-years (DALYs). Despite its prevalence, migraine remains significantly under-diagnosed and undertreated. The burden of migraine extends far beyond the attack itself — between attacks, anticipatory anxiety, activity avoidance, and the impact on employment, relationships, and quality of life are substantial. Effective migraine management requires a comprehensive approach: accurate diagnosis, acute attack management with triptans or NSAIDs, identification and avoidance of personal triggers, and preventive pharmacotherapy when attacks occur ≥4 days/month or are particularly disabling.

Epilepsy affects approximately 50 million people globally — a lifelong condition requiring adherence to antiepileptic drugs (AEDs) that may be lifelong. Modern antiepileptic pharmacology has expanded dramatically over the past three decades — from phenobarbitone, phenytoin, and carbamazepine, to the introduction of valproate, lamotrigine, topiramate, oxcarbazepine, levetiracetam, and multiple newer agents. The goal of epilepsy management is complete seizure freedom with minimum drug toxicity — 70% of patients achieve seizure freedom on AEDs, allowing many to eventually withdraw medication after prolonged seizure-free periods.

Malaria remains a major global public health emergency — the WHO estimates 247 million malaria cases and 619,000 malaria deaths annually, predominantly in sub-Saharan Africa. The discovery that artemisinin-based combination therapies (ACTs) dramatically outperform previous treatments has been transformative — ACT implementation has saved millions of lives. However, emerging partial artemisinin resistance in Southeast Asia represents an increasing threat to global malaria control.

Nausea and Vomiting Management Context

Nausea and vomiting are among the most disabling symptoms in oncology patients — impacting quality of life, nutritional status, hydration, and treatment adherence. Despite advances in antiemetic pharmacology (5-HT3 antagonists, NK1 antagonists, dexamethasone), chemotherapy-induced nausea and vomiting (CINV) remains incompletely controlled — particularly delayed CINV (>24 hours post-chemotherapy). The triple antiemetic regimen (5-HT3 + NK1 + dexamethasone) represents the current gold standard for highly emetogenic chemotherapy, achieving complete emesis control in 70–80% of patients during the acute phase and 60–70% during the delayed phase.

Evidence Base and Quality Standards

The active ingredients in this product range have been evaluated in landmark randomised controlled trials and systematic reviews, supported by major international guidelines including those from the International Headache Society (IHS), European Federation of Neurological Societies (EFNS), WHO, MASCC/ASCO antiemetic guidelines, and national specialist bodies. GMP-compliant manufacturing ensures consistent product quality, identity, and safety across all batches.

Patient Safety and Medication Adherence

Adherence to neurological medications — antiepileptics, migraine preventives, antimalarials, and antidepressants — is critical for optimal outcomes. For antiepileptic drugs, even a single missed dose can trigger breakthrough seizures with potentially catastrophic consequences (status epilepticus, injury, drowning). For migraine preventives (valproate, topiramate, flunarizine, amitriptyline), consistent daily dosing for at least 3 months is required before efficacy can be assessed — premature discontinuation due to early side effects or perceived lack of benefit is a major cause of preventive therapy failure. For antimalarial treatment, completing the full prescribed course is essential — incomplete treatment leads to treatment failure, recrudescence, and contributes to drug resistance development.

Polypharmacy risks are particularly significant in neurological and psychiatric patients — drug-drug interactions in this population can cause dangerous outcomes: carbamazepine reducing oral contraceptive efficacy (unintended pregnancy); valproate dramatically increasing lamotrigine levels (toxicity); MAO inhibitor interactions with triptans, SSRIs, or amitriptyline (serotonin syndrome); QTc prolongation with combinations of thioridazine, antifungals, or fluoroquinolone antibiotics. A comprehensive medication review before any new prescription in these patients is not optional — it is a clinical safety imperative.

Special Populations Requiring Additional Attention

Elderly patients receiving antiemetics, antiepileptics, and psychiatric medications face heightened risks: metoclopramide extrapyramidal reactions are more common and severe in the elderly; amitriptyline’s anticholinergic effects (confusion, urinary retention, falls) place elderly patients at unacceptable risk; benzodiazepine-amitriptyline combinations can cause respiratory depression and falls. For women of childbearing age: valproate/divalproex, topiramate, and carbamazepine all carry teratogenicity risks requiring counselling and contraception planning before and during therapy. Pregnancy requires specialist review of all neurological, psychiatric, and antimalarial medications — the benefit-risk calculus changes dramatically when foetal wellbeing is considered alongside maternal health management.

Important Medical Disclaimer

This product information guide is provided for general educational purposes only, prepared in accordance with YMYL (Your Money Your Life) content standards. All information draws on regulatory prescribing information, peer-reviewed pharmacological and clinical literature, and established guidelines. It does not replace professional medical advice, diagnosis, or treatment from a qualified neurologist, psychiatrist, infectious disease specialist, rheumatologist, or pharmacist. Self-diagnosis and self-treatment of neurological, psychiatric, infectious, and autoimmune conditions can be dangerous and life-threatening. Always consult a qualified healthcare professional before starting, changing, or stopping any medication.